Hyperviscosity is a condition in which blood becomes abnormally thick, slowing its flow through blood vessels and reducing oxygen delivery to organs. When blood thickens beyond a critical point, it can trigger a medical emergency called hyperviscosity syndrome, which classically presents with three hallmark problems: neurological symptoms, vision changes, and bleeding from mucous membranes (such as the gums or nose).
How Blood Thickness Affects Flow
Blood viscosity describes how easily blood moves through your vessels. Thicker blood meets more resistance, which means your heart has to work harder to push it through. The relationship between viscosity and flow is inversely proportional: as viscosity increases, the rate of blood flow decreases for any given blood pressure. This is why even a modest increase in blood thickness can meaningfully reduce circulation, especially in the smallest blood vessels where organs like the brain, eyes, and kidneys receive their oxygen supply.
Two main factors determine how thick your blood is. The first is the concentration of proteins dissolved in the liquid portion (plasma). The second is the proportion of red blood cells relative to the total blood volume, measured as hematocrit. Either one rising too high can push viscosity into a dangerous range.
What Causes Blood to Become Too Thick
Excess Proteins in the Plasma
Certain blood cancers cause the immune system to overproduce large antibody proteins that crowd the plasma and dramatically increase its thickness. The most common culprit is Waldenström macroglobulinemia, a cancer of white blood cells that churns out massive quantities of a large antibody called IgM. In studies of these patients, no one with IgM levels below 3,000 mg/dL developed symptomatic hyperviscosity. But patients whose IgM climbed to 6,000 mg/dL or higher had nearly a five-fold increased risk of developing the syndrome, and about 77% of those patients needed emergency plasma exchange.
Multiple myeloma, another blood cancer, can also cause hyperviscosity through overproduction of different antibody types, though it does so less frequently than Waldenström because the antibodies involved are smaller and less prone to forming large clumps in the bloodstream.
Too Many Red Blood Cells
When red blood cell production spirals out of control, as it does in polycythemia vera, the hematocrit rises and the blood becomes sludge-like. The relationship between hematocrit and viscosity is not a straight line. At normal levels the effect is modest, but as hematocrit climbs above 45%, viscosity begins to rise steeply, creating progressively greater resistance to blood flow. This is why treatment for polycythemia vera targets keeping hematocrit below 45%, a threshold established through randomized trials showing reduced clotting risk.
The Classic Triad of Symptoms
Hyperviscosity syndrome produces symptoms because sluggish blood fails to deliver enough oxygen to tissues, and the increased pressure in small vessels leads to leakage and damage. Three categories of symptoms appear most often together:
- Neurological problems: Headaches, dizziness, and confusion are often the earliest signs. As viscosity worsens, patients may experience difficulty hearing, unsteadiness, seizures, or even stroke-like episodes and loss of consciousness.
- Vision changes: The tiny vessels in the retina are especially vulnerable. Blurred or distorted vision can develop as retinal blood vessels become engorged and start to leak. An eye exam may reveal swollen, irregularly shaped veins and small hemorrhages across the retina.
- Mucosal bleeding: Spontaneous nosebleeds, bleeding gums, and oozing from mucous membranes occur because the overloaded small vessels rupture and because the excess proteins can interfere with normal clotting function.
Not everyone presents with all three. Some people first notice only persistent headaches or unexplained nosebleeds. Other organ systems can be affected too: the kidneys may begin to fail, the heart may struggle against the increased resistance, and the extremities may develop poor circulation.
How Hyperviscosity Is Diagnosed
A blood viscosity test directly measures how thick a blood sample is. Doctors can test either serum (the liquid left after blood clots) or plasma (the liquid portion with clotting factors still present). The difference between the two measurements correlates with fibrinogen concentration, one of the clotting proteins, so running both tests together provides extra diagnostic information at minimal additional cost.
Beyond the viscosity test itself, routine blood work often reveals clues. A very high total protein level or an extremely elevated antibody count raises immediate suspicion. In patients with polycythemia vera, a hematocrit well above the normal range (roughly 36% to 45% depending on sex) points toward viscosity-driven symptoms. Doctors also examine the retina, since the characteristic changes in the tiny blood vessels there can confirm that hyperviscosity is causing real tissue damage.
How It Is Treated
Hyperviscosity syndrome is treated as an emergency. The priority is to lower blood thickness quickly enough to restore adequate circulation and prevent organ damage.
When excess proteins are the cause, the primary treatment is plasma exchange (plasmapheresis). During a session, blood is drawn from the body, the protein-heavy plasma is separated and discarded, and replacement fluid is returned. Each session typically removes about 25% of the patient’s plasma volume. Symptoms often improve rapidly, sometimes within hours, because the procedure physically removes the large proteins clogging the bloodstream. However, plasma exchange is a bridge, not a cure. Chemotherapy or other cancer-directed treatment is needed to stop the underlying overproduction of abnormal proteins.
When the problem is too many red blood cells, phlebotomy (the controlled removal of blood) is the go-to approach. By drawing off blood and reducing the red cell concentration, viscosity drops and flow improves. For polycythemia vera patients, the goal is to keep hematocrit consistently below 45% through regular phlebotomy sessions, sometimes combined with medication that slows red blood cell production.
In settings where plasma exchange equipment is not available, doctors may perform phlebotomy with simultaneous fluid replacement as a temporary measure to reduce viscosity while arranging definitive treatment.
Why Speed Matters
The organs most at risk during hyperviscosity are those with the finest blood vessel networks: the brain, eyes, and kidneys. Prolonged sluggish flow to these organs can cause damage that does not fully reverse even after viscosity returns to normal. Strokes, permanent vision loss, and kidney injury are all possible if treatment is delayed. This is why hyperviscosity syndrome is classified as an oncologic emergency, and why treatment begins as soon as the diagnosis is suspected rather than waiting for confirmatory test results.
With prompt plasma exchange or phlebotomy, most patients experience rapid symptom relief. The long-term outlook depends largely on the underlying condition driving the viscosity increase and how well it responds to treatment.